Entrada Therapeutics TRDA
NASDAQ TRDA
$5.38 -0.30 (-5.28%)
At close: Oct 2, 2026 · 4:00 PM EDT

Entrada Therapeutics (TRDA) Gains from Sales and Divestitures (2020 - 2022)

Updated

Entrada Therapeutics (TRDA) recorded Gains from Sales and Divestitures of -$1,000 in Q4 2022, compared with $79,000 a year earlier.

Analysis

Entrada Therapeutics (TRDA) Gains from Sales and Divestitures (2020 - 2022) Analysis & Trends

On a TTM basis, Entrada Therapeutics' Gains from Sales and Divestitures came in at -$77,000 as of Dec 31, 2022; for FY2021, it came in at -$74,000.

  • Across earlier years, Gains from Sales and Divestitures came in at -$20,000 in FY2020.
  • Quarterly Gains from Sales and Divestitures has ranged from -$153,000 in Q3 2021 to $79,000 in Q4 2021 over the past five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Entrada Therapeutics 209.48 Mn 209.48 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 -1,000.00
Sep 30, 2022 -2,000.00
Dec 31, 2021 79,000.00
Sep 30, 2021 -153,000.00
Dec 31, 2020 -13,000.00
API Access

Entrada Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=TRDA&period=max&api_key=YOUR_API_KEY